Article
Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment.
Medicine - 1 Jun 2018
Uchino Junji, Nakao Akira, Tamiya Nobuyo, Kaneko Yoshiko, Yamada Tadaaki, Yoshimura Kenichi, Fujita Masaki, Takayama Koichi
Abstract excerpt
BACKGROUND: Advances in epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment led to research on the mechanism of the resistance have revealed that an occurrence of T790M gene mutation generated in exon 20 of the EGFR gene is associated with approximately 50% to 60% of observed resistance. Osimertinib, a 3rd-generation EGFR-TKI, has been shown to be effective against both EGFR tyrosine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.